Your browser doesn't support javascript.
loading
Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden.
Öfverholm, Anna; Einbeigi, Zakaria; Wigermo, Antonia; Holmberg, Erik; Karsson, Per.
Afiliação
  • Öfverholm A; Department of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, 413 45 Gothenburg, Sweden.
  • Einbeigi Z; Department of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, 413 45 Gothenburg, Sweden.
  • Wigermo A; Faculty of Medicine, Umeå University, 901 87 Umeå, Sweden.
  • Holmberg E; Department of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, 413 45 Gothenburg, Sweden.
  • Karsson P; Department of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, 413 45 Gothenburg, Sweden.
Genes (Basel) ; 10(12)2019 12 16.
Article em En | MEDLINE | ID: mdl-31888263
ABSTRACT
Women with BRCA variants have a high lifetime risk of developing breast and ovarian cancer. The aim of this study was to investigate the standard incidence ratios (SIR) for breast and ovarian cancer and standard mortality ratios (SMR) in a population-based cohort of women in Western Sweden, under surveillance and after risk reducing surgery. Women who tested positive for a BRCA variant between 1995-2016 (n = 489) were prospectively registered and followed up for cancer incidence, risk reducing surgery and mortality. The Swedish Cancer Register was used to compare breast and ovarian cancer incidence and mortality with and without risk reducing surgery for women with BRCA variants in comparison to women in the general population. SIR for breast cancer under surveillance until risk-reducing mastectomy (RRM) was 14.0 (95% CI 9.42-20.7) and decreased to 1.93 (95% CI 0.48-7.7) after RRM. The SIR for ovarian cancer was 124.6 (95% CI 59.4-261.3) under surveillance until risk reducing salpingo-oophorectomy (RRSO) and decreased to 13.5 (95% CI 4.34-41.8) after RRSO. The SMR under surveillance before any risk reducing surgery was 5.56 (95% 2.09-14.8) and after both RRM and RRSO 4.32 (95% CI 1.62-11.5). Women with cancer diagnoses from the pathology report after risk reducing surgery were excluded from the analyses. Risk reducing surgery reduced the incidence of breast and ovarian cancer in women with BRCA variants. However, overall mortality was significantly increased in comparison to the women in the general population and remained elevated even after risk reducing surgery. These findings warrant further research regarding additional measures for these women.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Proteína BRCA1 / Proteína BRCA2 Tipo de estudo: Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Genes (Basel) Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Proteína BRCA1 / Proteína BRCA2 Tipo de estudo: Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Genes (Basel) Ano de publicação: 2019 Tipo de documento: Article